Breaking News

Tweet TWEET

Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference

 Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare
                                  Conference

PR Newswire

ANAHEIM, Calif., Sept. 5, 2013

ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) announced today that executive management will host investor
meetings and will be a participant in a fireside chat session at the Morgan
Stanley Global Healthcare Conference in New York City on September 10, 2013 at
4:40 PM ET/1:40 PM PT. The Conference does not accommodate formal
presentations or the use of slides so there will not be a webcast
presentation.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor also provides specialty contract
manufacturing services to the global pharmaceutical industry through its
wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P.
Acthar® Gel (repository corticotropin injection), an injectable drug that is
approved by the FDA for the treatment of 19 indications. Of these 19
indications, Questcor currently generates substantially all of its net sales
from the following approved indications: the treatment of proteinuria in the
nephrotic syndrome of the idiopathic type, or NS, the treatment of acute
exacerbations of multiple sclerosis, or MS, in adults, the treatment of
infantile spasms, or IS, in infants and children under two years of age, and
the treatment of certain rheumatology related conditions. With respect to
nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a
remission of proteinuria in the nephrotic syndrome without uremia of the
idiopathic type or that due to lupus erythematosus." Questcor has announced
its intent to initiate a pilot commercialization effort for Acthar for the
treatment of respiratory manifestations of symptomatic sarcoidosis. The FDA
approved package insert for Acthar includes "symptomatic sarcoidosis" under
the heading "Respiratory Diseases". Questcor is also exploring the
possibility of developing markets for other on-label indications and the
possibility of pursuing FDA approval of additional indications not currently
on the Acthar label where there is high unmet medical need. Questcor also has
agreed to acquire certain international rights for Synacthen® (tetracosactide)
and Synacthen Depot®, and has licensed the right to develop and seek FDA
approval for these products in the United States. For more information about
Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

Website: http://www.questcor.com
Contact: EVC Group, Gregory Gin, 646-445-4801, Patty Eisenhaur, 951-316-0577,
Doug Sherk, 415-652-9100, Janine McCargo, 646-688-0425
 
Press spacebar to pause and continue. Press esc to stop.